Skip Ribbon Commands
Skip to main content
Sign In



Allen & Overy advises SmartPractice on the acquisition of the Epicutantest Hermal / TROLAB patch test business from Almirall Hermal


08 January 2014

Allen & Overy has advised SmartPractice, the global leader in diagnostic patch test allergens and chambers for the diagnosis of allergic contact dermatitis, on the acquisition of Epicutantest Hermal / TROLAB patch test business from Almirall.  

The portfolio consists of 267 patch test allergens – the world’s largest offering of regulated allergens for diagnostic patch testing. All patch test allergens have been approved by the German Paul Ehrlich Institute. The parties have agreed not to disclose the purchase price of the transaction.

Under SmartPractice, the TOLAB / Epicutantest Hermal patch test allergens will continue to be produced by the same team of experienced specialists in the same facility in Reinbek, near Hamburg.

The Allen & Overy team comprised partners Dr Hans Schoneweg, Malte-M. Holthaus (both corporate/M&A, Hamburg), Dr Olaf Otting (public law, Frankfurt), Dr Jens Matthes (IP, Dusseldorf) and Markulf Behrendt (employment, Hamburg), counsel Marie-Luise von Buchwaldt, senior associates Dr Rüdiger Klüber, Daniel Martin Schulz and Dr Christian Hilmes (all corporate/M&A, Hamburg) as well as associates Stefanie Waibel (public law, Frankfurt), Juliane Dieckmann-Keden (corporate/M&A, Hamburg) and Sören Seidel (employment, Hamburg).

Tax advice has been provided by Crowe Horwath.



News search

Related people

  • Add comment (optional)